14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
As of Jul 24, 2026, Avanos Medical, Inc. (AVNS) is the stronger overall head-to-head candidate over Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of (RBOT.WS) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AVNS carries a Unified Composite Score of 56.7/100 (HOLD) at $24.99 (20.0x Forward P/E, 5.4% operating margin), whereas RBOT.WS carries 50.1/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AVNS vs RBOT.WS. Trailing 12-month operating profitability (AVNS 5.4% vs RBOT.WS N/A) and valuation multiples (AVNS 20.0x vs RBOT.WS N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Orthopedic, Prosthetic & Surgical Appliances & Supplies value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ AVNS vs RBOT.WS Key Questions & Quantitative Answers
As of Jul 24, 2026, Avanos Medical, Inc. (AVNS) is the stronger overall head-to-head candidate over Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of (RBOT.WS) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AVNS carries a Unified Composite Score of 56.7/100 (HOLD) at $24.99 (20.0x Forward P/E, 5.4% operating margin), whereas RBOT.WS carries 50.1/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin). Technically, AVNS sits in a Neutral phase (RSI 57.0, UNCLASSIFIED options structure) and RBOT.WS sits in a Neutral phase (RSI N/A, UNCLASSIFIED options structure).
AVNS leads the Growth & Scale pillar: AVNS posts +8.8% YoY revenue growth and -21.7% YoY earnings growth on $716M TTM revenue (50.0% gross margin, 5.4% operating margin), compared with RBOT.WS at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, AVNS generates $716M in USD-normalized revenue versus N/A for RBOT.WS. In operating R&D and SG&A reinvestment, AVNS deploys 44.6% of Rev ($319M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RBOT.WS.
AVNS screens cheaper on headline valuation multiples. AVNS trades at 20.0x Forward P/E, 30.7x Trailing P/E, N/M PEG, and 1.6x EV/Revenue (7.8% EBITDA margin), whereas RBOT.WS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVNS (-9.2% ROE) versus RBOT.WS (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, AVNS carries 33.0% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.22β · 6% Vol realized risk). By comparison, RBOT.WS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of Class A Common Stock at an exercise price of $345.00 (RBOT.WS) Research Suite
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Jul 24, 2026. For educational research only; not investment advice.